DITATE-DS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DITATE-DS (DITATE-DS).
DITATE-DS is a combination of dexamethasone, a corticosteroid with anti-inflammatory and immunosuppressant properties, and trimethoprim, a folate antagonist. Dexamethasone acts by binding to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response. Trimethoprim inhibits dihydrofolate reductase, blocking bacterial folate synthesis and exerting antibacterial effects.
| Metabolism | Dexamethasone is primarily metabolized by CYP3A4 to 6β-hydroxydexamethasone. Trimethoprim undergoes O-demethylation and N-oxidation via CYP450 enzymes. |
| Excretion | Renal (50-60% as unchanged drug and metabolites), biliary/fecal (40-50% as metabolites and unchanged drug). |
| Half-life | Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment. |
| Protein binding | 85-90% bound primarily to albumin, with minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.15-0.25 L/kg, indicating distribution primarily within extracellular fluid and moderate tissue binding. |
| Bioavailability | Oral: 90-100% (first-pass metabolism minimal). |
| Onset of Action | Oral: 30-60 minutes; intramuscular: 15-30 minutes; intravenous: 5-10 minutes. |
| Duration of Action | 4-6 hours for single dose; extended relief possible with sustained-release formulations. Duration prolonged in hepatic impairment. |
1 tablet (0.5 mg dexamethasone/5 mg cyproheptadine) orally every 8 hours, maximum 3 tablets daily.
| Dosage form | INJECTABLE |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment. For severe renal impairment (eGFR <30 mL/min/1.73 m²), use with caution and monitor for adverse effects. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Consider 50% dose reduction. Child-Pugh C: Avoid use due to lack of data. |
| Pediatric use | Children >2 years: 0.25 mg dexamethasone/2.5 mg cyproheptadine per 10 kg body weight orally every 8 hours, maximum 1.5 mg dexamethasone/15 mg cyproheptadine daily. |
| Geriatric use | Initiate at 0.5 tablet (0.25 mg dexamethasone/2.5 mg cyproheptadine) orally every 8 hours, titrate gradually to lowest effective dose. Monitor for electrolyte disturbances, hyperglycemia, and cognitive changes. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DITATE-DS (DITATE-DS).
| Breastfeeding | Corticosteroids pass into breast milk. M/P ratio for prednisolone is approximately 0.1-0.2. Doses up to 40 mg/day are considered compatible with breastfeeding if infant monitored for adrenal suppression. Avoid high-dose or long-term use. |
| Teratogenic Risk | DITATE-DS is a corticosteroid combination. In first trimester, risk of oral clefts increased. Second and third trimesters: risk of fetal adrenal suppression, low birth weight, and preterm delivery. Chronic use may cause intrauterine growth restriction. |
■ FDA Black Box Warning
Not available; no FDA black box warning reported.
| Serious Effects |
Hypersensitivity to components, systemic fungal infections (for corticosteroid component), megaloblastic anemia due to folate deficiency (for trimethoprim component), concomitant methotrexate (due to additive folate antagonism).
| Precautions | Immunosuppression, increased risk of infections, adrenal suppression, masking of infection signs, gastrointestinal perforation, osteoporosis, and trimethoprim-associated hyperkalemia and bone marrow suppression. |
Loading safety data…
| Fetal Monitoring |
| Monitor blood glucose, blood pressure, and signs of infection in mother. For fetus, monitor growth via ultrasound and assess for adrenal suppression if used long-term or high-dose. |
| Fertility Effects | May suppress hypothalamic-pituitary-adrenal axis and reduce fertility in both males and females. Oligomenorrhea or amenorrhea possible. Effects reversible upon discontinuation. |